

Sintaho Profile

公司简介

重庆兴泰濠制药有限公司，为重庆泰濠制药全资控股子公司，于2016年成立于中国重庆国际生物城。

Chongqing Sintaho Pharmaceutical Co., Ltd., is a wholly-owned subsidiary of Chongqing Taihao Pharma., founded in Chongqing International Biological Park, China, in 2016.

兴泰濠以化学合成为核心，专注于抗肿瘤治疗领域的细胞毒和/或高活性APIs，ADC化合物（毒素、连接子、毒素-连接子），代谢和内分泌治疗领域的GLP-1 APIs的开发、GMP生产和全球销售。Sintaho takes chemosynthesis as the core, specialized in the development, GMP manufacture and the global sales of cytotoxic and/or high potency APIs, ADC compounds (payload, linker, and payload-linker) in oncology, GLP-1 APIs in metabolism and endocrinology.

生产和注册策略的合同生产服务，特别是细胞毒和/或高活性APIs和ADC化合物（毒素、连接子、毒素-连接子）。

In addition, Sintaho provides contract manufacturing, satisfying the GMP manufacture and registration strategies of new drugs, particularly cytotoxic and/or high potency APIs, and ADC compounds (payload, linker, and payload-linker).

Business Model

业务模式

研发、GMP生产和全球销售 / Development, GMP Manufacture, and the Global Sales

合同制造 / Contract Manufacturing

GLP-1 APIs

| GLP-1 API / GLP-1 API | CAS# |
|---|--------------|
| 司美格鲁肽 Semaglutide | 910463-68-2 |
| 替尔泊肽 Tirzepatide | 2023788-19-2 |
| 奥格列龙半钙盐 Orforglipron hemi-calcium hydrate | 2212021-26-4 |
| 相关化合物 / Relevant Components | CAS# |
| 司美格鲁肽N-1(SE02) Semaglutide N-1(SE02) | NA |
| 侧链 tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu | 1118767-16-0 |
| 8-(2-羟基苯甲酰胺基)辛酸钠 Salcaprozate Sodium (SNAC) | 203787-91-1 |

免责声明：本目录中的任何信息（包括对任何产品或服务的任何引用）均不构成销售要约，也不应被解释为代表销售要约。受有效专利保护的产品不提供或供应用于商业用途。但是，如果存在此类监管豁免，则此类产品的研究数量可以用于监管提交。买方应对各自市场的专利方案进行独立评估，并负责所有与专利相关的责任。

Disclaimer: No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities.

地址：中国重庆市巴南区麻柳嘴镇柳青路600号（邮编：401319）

Add: #600, Liuqing Rd., Maliuzui Town, Banan District, Chongqing 401319, China

电话 Tel: +86-23-88961278 邮箱 E-mail: sales@sintaho.com

| 小分子API / Small Molecule API | CAS# | 小分子API / Small Molecule API | CAS# |
|---|--------------|--|--------------|
| 甲磺酸艾日布林 Eribulin Mesylate | 441045-17-6 | 枸橼酸伊沙佐米 Ixazomib Citrate | 1072833-77-2 |
| 替尼布林 Tirbanibulin | 897016-82-9 | 培美曲塞二钠七水合物 Pemetrexed Disodium Heptahydrate | 357166-29-1 |
| 阿扎胞苷 Azacitidine | 320-67-2 | 奥拉帕利 Olaparib | 763113-22-0 |
| 紫杉醇(半合成) Paclitaxel Semi-Synthetic | 33069-62-4 | 芦比替定 Lurbinectedin | 497871-47-3 |
| 多西他赛无水物 Docetaxel Anhydrous | 114977-28-5 | 吡托布鲁替尼 Pirtobrutinib | 2101700-15-4 |
| 卡巴他赛丙酮合物 Cabazitaxel Acetone Solvate | 1426815-65-7 | 舒泽曲近 Suzetrigine | 2649467-58-1 |
| 卡非佐米 Carfilzomib | 868540-17-4 | 卡利拉嗪 Cariprazine | 839712-12-8 |

独立的ADC化合物GMP车间已建成投产，专业提供ADC药物临床所需GMP批次和商业化批次的生产服务。

An independent GMP workshop of ADC compounds has been established and put into production, to professionally provide the manufacturing service of clinical trials and commercial batches of ADC drugs.

ADC化合物/ADC Compounds

| 连接子品名 / Linker Name | CAS#或分类 / CAS# or Classification | 连接子品名 / Linker Name | CAS#或分类 / CAS# or Classification |
|---------------------------|--|---------------------|-----------------------------------|
| MC-Val-Cit-PAB-PNP | 159857-81-5 | MAL-di-EG-OPFP | 不可切割的连接子 Non-cleavable Linkers |
| Val-Cit-PAB | 159857-79-1 | MAL-tri-EG-OPFP | |
| Fmoc-Val-Cit-PAB | 159858-22-7 | MAL-tetra-EG-OPFP | |
| Fmoc-Val-Cit-PAB-PNP | 863971-53-3 | N3-di-EG-OPFP | |
| Phe-Lys(Trt)-PAB | 1116085-99-4 | N3-tri-EG-OPFP | |
| Fmoc-Phe-Lys(Trt)-PAB-PNP | 1116086-09-9 | N3-tetra-EG-OPFP | |
| MC-GGFG | 2413428-36-9 | ALD-BZ-OSu | |
| MC-GGFG-Glycolic acid | 1599440-25-1 | ALD-di-EG-OSu | |
| Mal-PEG4-Val-Glu(tBu)-PAB | ————— | ALD-tetra-EG-OSu | |
| Py-ds-Prp-OSu | 谷胱甘肽敏感的二硫键连接子 Glutathione-sensitive Disulfide Linker | ALD-di-EG-OPFP | |
| Py-ds-dmBut-OSu | | ALD-tetra-EG-OPFP | |
| Py-ds-dmBut-OPFP | | PHA-di-EG-OPFP | |
| Py-ds-Prp-OPFP | | PHA-tetra-EG-OPFP | |
| MAL-HA-OSu | 不可切割的连接子 Non-cleavable Linkers | ————— | |

毒素-连接子 / Payload - Linker

德鲁替康 Deruxtecan (CAS# 1599440-13-7)

| | |
|-------------------------------|------------------------------------|
| MC-VC-PAB-PNP + Eribulin | MC-VC-PAB-PNP + Azacitidine |
| MC-VC-PAB-PNP + Pomalidomide | MC-VC-PAB-PNP + Pemetrexed |
| MC-VC-PAB-PNP + Lenalidomide | MC-VC-PAB-PNP + Gemcitabine |
| MC-VC-PAB-PNP + Deoxycytidine | 持续开发中 Under continuous development |

相关化合物 / Relevant Components

| | |
|--|---|
| 甲磺酸依喜替康 Exatecan mesylate (CAS# 169869-90-3) | MC-Gly-Gly-Phe-Gly-NH-CH ₂ -O-CH ₂ COOH (CAS# 1599440-25-1) |
|--|---|